| 1434 |
National Cancer Institute |
Html |
en |
Chronic Lymphocytic Leukemia Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of chronic lymphocytic leukemia. |
| CLL | 0.563454 |
| German CLL Study | 0.551069 |
| monoclonal B-cell lymphocytosis | 0.528403 |
| Engl J Med | 0.555252 |
| trial | 0.525679 |
| leukemia group | 0.552678 |
| M. Prolymphocytic leukemia | 0.545972 |
| Routine chronic administration | 0.534661 |
| lymphocytic leukemia patients | 0.591222 |
| Leukemia group B. | 0.542105 |
| CLL Study Group | 0.54078 |
| cyclophosphamide | 0.529502 |
| Byrd JC | 0.527428 |
| Keating MJ | 0.535835 |
| advanced chronic | 0.539233 |
| patients | 0.592663 |
| Lymphocytic Leukemia Study | 0.593872 |
| T-cell prolymphocytic leukemia | 0.546745 |
| refractory high-risk chronic | 0.534243 |
| refractory chronic | 0.528565 |
| Adult Leukemia Group | 0.542021 |
| Leuk Lymphoma | 0.531402 |
| Lymphocytic Leukemia section | 0.595648 |
| fludarabine | 0.547348 |
| alemtuzumab versus fludarabine | 0.527105 |
|
| untreated B chronic | 0.530625 |
| et al. | 0.648755 |
| treatment | 0.535273 |
| small lymphocytic lymphoma | 0.590269 |
| French Cooperative Group | 0.528743 |
| German Chronic Lymphocytic | 0.583925 |
| Relapsed Chronic Lymphocytic | 0.579501 |
| acute myeloid leukemia | 0.53754 |
| stem cell | 0.529413 |
| Leukemia Study Group | 0.55235 |
| rituximab | 0.530116 |
| fludarabine-refractory B-cell chronic | 0.53547 |
| CLL therapy | 0.52689 |
| chronic lymphoid leukemia | 0.573599 |
| CLL Study Group. | 0.526303 |
| Abstract | 0.627578 |
| therapy | 0.53011 |
| Clin Oncol | 0.713099 |
| hairy cell leukemia | 0.553353 |
| blood | 0.56117 |
| chronic lymphocytic leukemia | 0.965039 |
| chronic lymphocytic leukaemia | 0.705583 |
| previously untreated patients | 0.578343 |
| allogeneic stem cell | 0.525551 |
|
CLICK HERE |
| 1544 |
National Cancer Institute |
Html |
en |
Adult Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of adult acute myeloid leukemia. |
| adult aml | 0.716289 |
| red blood cells | 0.594071 |
| cancer treatment | 0.467513 |
| blood -forming cells | 0.4491 |
| acute myeloblastic leukemia | 0.44585 |
| acute myelogenous leukemia | 0.445245 |
| chemotherapy | 0.473847 |
| PDQ cancer information | 0.503817 |
| white blood cells | 0.675945 |
| clinical trials | 0.938073 |
| mature blood cells | 0.50039 |
| cancer information summary | 0.459101 |
| clinical trial | 0.615294 |
| stem cells | 0.519631 |
| stem cell transplant | 0.480735 |
| acute granulocytic leukemia | 0.446114 |
| Myeloid Leukemia Treatment | 0.448761 |
| blood cells | 0.735668 |
| radiation therapy | 0.468603 |
| treatment | 0.673705 |
| myeloid stem cell | 0.438755 |
| stored stem cells | 0.437216 |
| immature blood cells | 0.448693 |
| arsenic trioxide | 0.473356 |
|
| cancer cells | 0.602593 |
| specific cancer cells | 0.456728 |
| recurrent adult aml | 0.474546 |
| untreated adult aml | 0.465491 |
| acute myeloid leukemia | 0.930922 |
| stem cell | 0.533281 |
| treatment clinical trials | 0.44329 |
| blood stem cells | 0.488116 |
| National Cancer Institute | 0.460343 |
| spinal cord | 0.512703 |
| normal cells | 0.467456 |
| myeloid stem cells | 0.482174 |
| new treatment | 0.480473 |
| white blood cell | 0.463646 |
| combination chemotherapy | 0.472241 |
| bone marrow | 0.747056 |
| cells | 0.827248 |
| acute promyelocytic leukemia | 0.5928 |
| cancer clinical trials | 0.452604 |
| acute nonlymphocytic leukemia | 0.445812 |
| acute lymphoblastic leukemia | 0.434651 |
| acute leukemia | 0.43925 |
| cancer | 0.808047 |
| standard treatment | 0.467846 |
|
CLICK HERE |
| 1584 |
National Cancer Institute |
Html |
en |
Anal Cancer Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of anal cancer. |
| cancer treatment | 0.433322 |
| diagnose anal cancer | 0.423593 |
| Anal Cancer Treatment | 0.419952 |
| metastatic anal cancer | 0.412176 |
| Frequent anal redness | 0.384126 |
| body | 0.434753 |
| PDQ cancer information | 0.446236 |
| clinical trial search | 0.504831 |
| anal cancer spreads | 0.410812 |
| clinical trials | 0.887836 |
| cancer information summary | 0.419039 |
| clinical trial | 0.647154 |
| anus | 0.449257 |
| patients | 0.429875 |
| treatment clinical trial | 0.380816 |
| NCI PDQ cancer | 0.384659 |
| malignant tumor cells | 0.380765 |
| radiation therapy | 0.718553 |
| Treatment Editorial Board | 0.382929 |
| human immunodeficiency virus | 0.375987 |
| rectum | 0.3805 |
| General information | 0.426863 |
| general cancer information | 0.376766 |
| treatment | 0.612453 |
| abdominoperineal resection | 0.403255 |
|
| receptive anal intercourse | 0.384527 |
| new cancer treatments | 0.377037 |
| NCI-supported cancer | 0.425485 |
| cancer cells | 0.46124 |
| Cancer Information Service | 0.376813 |
| sphincter muscles | 0.384557 |
| treatment clinical trials | 0.40741 |
| National Cancer Institute | 0.461854 |
| Recurrent anal cancer | 0.435676 |
| new treatment | 0.505194 |
| external-beam radiation therapy | 0.454262 |
| IIIA anal cancer | 0.402258 |
| IIIB anal cancer | 0.401297 |
| anal cancer | 0.792189 |
| new treatment options | 0.426789 |
| anal opening | 0.376839 |
| cancer clinical trials | 0.506964 |
| stage | 0.400723 |
| Local resection | 0.453758 |
| tumor | 0.401265 |
| comprehensive cancer information | 0.375327 |
| internal radiation therapy | 0.496063 |
| cancer | 0.970468 |
| information | 0.453326 |
|
CLICK HERE |
| 1872 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer de células de transición de pelvis renal y de uréter (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer de células de transición de pelvis renal y de uréter. |
| Compton CC | 0.310067 |
| prognostic factors | 0.311079 |
| Roth BJ | 0.353197 |
| transitional cell carcinoma | 0.558604 |
| Sin embargo | 0.332107 |
| Ta Carcinoma | 0.313126 |
| Elson PJ | 0.309122 |
| California Oncology Group | 0.314515 |
| 7th ed | 0.310032 |
| tumores renales | 0.309511 |
| pelvis renal | 0.960657 |
| Instituto Nacional | 0.312591 |
| metástasis distantes | 0.32208 |
| células transicionales recidivantes | 0.361913 |
| pared pélvica renal | 0.316324 |
| parénquima renal t3 | 0.317938 |
| cooperative group study | 0.316918 |
| Cooperative Oncology Group | 0.315511 |
| tejido renal | 0.313083 |
| metastatic transitional cell | 0.319135 |
| preliminary report from | 0.31524 |
| group study | 0.325781 |
| Einhorn LH | 0.327583 |
| urinary tract | 0.331593 |
| función renal | 0.325386 |
|
| Northern California Oncology | 0.31495 |
| upper urinary tract | 0.318654 |
| effective chemotherapy regimen | 0.317306 |
| Oncology Group study | 0.317114 |
| Nocks BN | 0.30983 |
| Cancer Staging Manual | 0.321607 |
| PDQ Tratamiento | 0.309071 |
| Renal pelvic tumors | 0.315825 |
| New York | 0.30907 |
| Daly JJ | 0.308968 |
| with paclitaxel | 0.310585 |
| Clin Oncol | 0.437926 |
| parénquima renal | 0.327814 |
| Byrd DR | 0.309554 |
| urothelial carcinoma | 0.398878 |
| gallium combination chemotherapy | 0.316792 |
| insuficiencia renal | 0.313531 |
| Eastern Cooperative Oncology | 0.315974 |
| renal pelvis | 0.422209 |
| Oncology Group | 0.324511 |
| Tis Carcinoma | 0.313191 |
| metastatic urothelial carcinoma | 0.363244 |
| AJCC Cancer Staging | 0.322547 |
| Edge SB | 0.31008 |
|
CLICK HERE |
| 1909 |
National Cancer Institute |
Html |
es |
Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica. |
| siguientes procedimientos | 0.425256 |
| células madre | 0.845072 |
| Chronic Myelogenous Leukemia | 0.438357 |
| leucemia linfoblástica aguda | 0.438362 |
| hueso compacto | 0.417479 |
| enlace drugs approved | 0.436902 |
| cromosoma filadelfia | 0.526385 |
| célula madre mieloide | 0.437781 |
| Sudores nocturnos | 0.404959 |
| células anormales.ampliar aspiración | 0.417986 |
| enlace medicamentos | 0.404489 |
| National Cancer Institute | 0.403419 |
| siguientes riesgos | 0.40277 |
|
| Instituto Nacional | 0.405884 |
| célula madre linfoide | 0.438967 |
| PDQ Tratamiento | 0.410126 |
| hijos.ampliar cromosoma filadelfia | 0.412419 |
| leucemia mielógena | 0.99599 |
| Physician Data Query | 0.412686 |
| laboratorio piezas | 0.403757 |
| leucemia mieloide aguda | 0.437955 |
| siguientes exámenes | 0.405471 |
| célula madre | 0.512002 |
| células sanguÃneas maduras | 0.448469 |
| ósea elabora células | 0.429135 |
| siguientes sumarios | 0.40998 |
|
CLICK HERE |
| 1986 |
National Cancer Institute |
Html |
es |
Linfedema (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre la anatomía, la patofisiología, las manifestaciones clínicas, el diagnóstico y el tratamiento del linfedema relacionado con el cáncer, una afección en la que se acumula líquido linfático en los tejidos y causa inflamación.. |
| after sentinel lymph | 0.313822 |
| Ridner SH | 0.344357 |
| group trial | 0.315465 |
| Sin embargo | 0.344649 |
| upper extremity lymphedema | 0.331183 |
| linfedema usa | 0.380409 |
| controlled trial with | 0.318641 |
| CA Cancer | 0.317513 |
| ganglios linfáticos centinelas | 0.349529 |
| arm lymphedema after | 0.317881 |
| extremity lymphedema after | 0.335236 |
| Cancer statistics | 0.316994 |
| treatment-related lymphedema | 0.324253 |
| lymphedema after breast | 0.383555 |
| ganglio centinela | 0.352856 |
| axillary sampling with | 0.313496 |
| conductos linfáticos subclavios | 0.335825 |
| Petrek JA | 0.323456 |
| Schmitz KH | 0.339884 |
| Sport Sci Rev | 0.321461 |
| controlled trial comparing | 0.313482 |
| randomized controlled | 0.341872 |
| Balancing lymphedema risk | 0.334354 |
| breast cancer-related lymphedema | 0.386776 |
| tronco linfático subclavio | 0.332389 |
|
| arm lymphedema | 0.323652 |
| axillary dissection with | 0.315734 |
| vena subclavia | 0.3286 |
| Care Cancer | 0.334426 |
| exercise versus deconditioning | 0.326793 |
| with axillary lymph | 0.315505 |
| ganglio linfático centinela | 0.380935 |
| with arm lymphedema | 0.319809 |
| Arch Phys Med | 0.320628 |
| discrepancia intramiembro | 0.359416 |
| Phys Med Rehabil | 0.321125 |
| breast carcinoma survivors | 0.322235 |
| lower-extremity lymphedema secondary | 0.313534 |
| with breast-cancer-related lymphedema | 0.31752 |
| Ahmed RL | 0.322704 |
| Clin Oncol | 0.373772 |
| breast cancer | 0.91318 |
| sentinel lymph | 0.326667 |
| Breast Cancer Study | 0.332383 |
| with or without | 0.326647 |
| Exerc Sport Sci | 0.322466 |
| axillary lymph | 0.328084 |
| Weight lifting | 0.32136 |
| Breast Cancer Res | 0.331771 |
|
CLICK HERE |
| 2011 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de pulmón (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar o vigilar el cáncer de pulmón. |
| lung cancer screening | 0.491865 |
| Berg CD | 0.308884 |
| UK Lung Cancer | 0.309828 |
| Cooperative Early Lung | 0.306877 |
| Lung Cancer Study | 0.310626 |
| lung cancer | 0.996403 |
| Reduced lung-cancer mortality | 0.308509 |
| American Cancer Society | 0.314872 |
| Sloan-Kettering Lung Study | 0.306329 |
| Extended lung | 0.305748 |
| lung-cancer screening | 0.305282 |
| Lung Screening Trial | 0.34779 |
| Preventive Services Task | 0.315666 |
| early lung cancer | 0.370281 |
| Cancer Res | 0.308506 |
| screening results | 0.305543 |
| exámenes detección | 0.3124 |
| Screening Trial | 0.41076 |
| lung-cancer mortality with | 0.308638 |
| Randomized Danish Lung | 0.306065 |
| CT screening | 0.322848 |
| Natl Cancer Inst | 0.348878 |
| small lung | 0.309116 |
| Lung Cancer Risk | 0.310447 |
| from baseline screening | 0.305357 |
|
| More lung | 0.305626 |
| Screening Trial with | 0.311542 |
| early stage lung | 0.306471 |
| Is curable lung | 0.306471 |
| cytologic screening | 0.312546 |
| Hocking WG | 0.305973 |
| Hopkins Lung Project | 0.306129 |
| CT screening according | 0.305575 |
| Danish Lung Cancer | 0.338861 |
| Lung Cancer Action | 0.32014 |
| randomised danish lung | 0.306155 |
| National Lung Screening | 0.345051 |
| Intern Med | 0.314222 |
| lung cancer detection | 0.362796 |
| Services Task Force | 0.31539 |
| Randomized Lung Cancer | 0.310797 |
| from semi-annual screening | 0.30542 |
| PLCO Cancer Screening | 0.310194 |
| Mayo Lung Project | 0.341943 |
| lung cancers detected | 0.306094 |
| Memorial Sloan-Kettering | 0.306282 |
| Cancer Action Project | 0.310925 |
| Lung Project revisited | 0.306785 |
| Cancer Screening Trial | 0.390805 |
|
CLICK HERE |
| 3460 |
National Cancer Institute |
Html |
es |
Coenzima Q10 (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer. |
| Natl Acad Sci | 0.506232 |
| animal models | 0.503048 |
| Lockwood K | 0.522246 |
| Friend leukemia virus | 0.50335 |
| Mol Aspects Med | 0.525442 |
| Prog Drug Res | 0.505422 |
| Exp Clin Res | 0.507107 |
| Ernster L | 0.506157 |
| Clin Investig | 0.504327 |
| vitamina q10 | 0.508703 |
| vitamin q10 | 0.549224 |
| Health Syst Pharm | 0.503499 |
| Chem Pathol Pharmacol | 0.515808 |
| Bliznakov EG | 0.512562 |
| Hanioka T | 0.504235 |
| coenzyme q10 | 0.845306 |
| with vitamin q10 | 0.522905 |
| reticuloendothelial system upon | 0.50329 |
| Res Commun Chem | 0.525595 |
| coenzima q10 | 0.990386 |
| Nylander M | 0.503126 |
| system upon stimulation | 0.503357 |
| coenzima q.10 | 0.50372 |
| Coenzyme Q10 administration | 0.515239 |
| patients with | 0.52239 |
|
| Clinical Aspects | 0.506167 |
| Folkers K | 0.720923 |
| patients treated with | 0.503528 |
| Osterborg A | 0.503093 |
| coenzima q10 resumen | 0.509859 |
| Commun Chem Pathol | 0.52121 |
| Moesgaard S | 0.509545 |
| Biophys Res Commun | 0.66246 |
| Chemother Rep | 0.503476 |
| Nordenbrand K | 0.502764 |
| Proc Natl Acad | 0.506461 |
| Apparent partial remission | 0.503092 |
| Biochem Biophys Res | 0.653978 |
| with nutritional antioxidants | 0.504649 |
| coenzima q10 ayuda | 0.51293 |
| Drugs Exp Clin | 0.50459 |
| conzima q10 | 0.506965 |
| Overvad K | 0.504381 |
| Clin Nutr | 0.503026 |
| serious deficiency | 0.503488 |
| coenzyme q10 concentrations | 0.523415 |
| radicales libres | 0.504036 |
| essential fatty acids | 0.503269 |
| Yamashita S | 0.503124 |
|
CLICK HERE |
| 15639 |
National Cancer Institute |
Html |
null |
Grants |
Learn about the different grants that are available, such as Research Projects Grants, SPORE Grants, career awards and cancer education grants, training grants, and others. |
|
|
CLICK HERE |
| 16842 |
National Cancer Institute |
Html |
en |
Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research |
The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here. |
| predoctoral fellows | 0.736483 |
| cancer nanobiotechnology | 0.632531 |
| optimal treatment | 0.545276 |
| Johns Hopkins University | 0.729715 |
| journal club | 0.539106 |
| novel cancer diagnostics | 0.713403 |
| program fosters | 0.562779 |
| steady state number | 0.670018 |
| epigenetic markers | 0.560601 |
| tumor boards | 0.538166 |
| NTCR program | 0.576419 |
| new frontier | 0.564875 |
| individual patient | 0.643505 |
| engineering/physics discipline | 0.563571 |
| physical sciences-oncology center | 0.676488 |
| lab course | 0.540911 |
| new modalities | 0.563 |
| cellular / cancer | 0.59221 |
| Johns Hopkins Institute | 0.669855 |
| dedicated annual symposium | 0.651728 |
| experimental facilities | 0.538368 |
| Vivo Cellular | 0.548936 |
| Molecular Imaging Center | 0.688968 |
| black-box input-output techniques | 0.710638 |
|
| scientific exploration | 0.554225 |
| clinical resources | 0.5443 |
| human diseases | 0.555299 |
| cancer cell functions | 0.720912 |
| clinical conferences | 0.540551 |
| high-throughput diagnostic tools | 0.682779 |
| non-viral delivery systems | 0.686087 |
| unique educational resources | 0.657197 |
| postdoctoral fellows | 0.715577 |
| Principal Investigator | 0.564913 |
| therapeutic tools | 0.551025 |
| Pancreatic Cancer Center | 0.731915 |
| Ludwick Center | 0.581555 |
| NTCR trainees | 0.59515 |
| cancer nanotechnology excellence | 0.742492 |
| outstanding trainees | 0.578764 |
| disease phenotype | 0.55677 |
| Comprehensive Cancer Center | 0.727928 |
| Cancer Genetics | 0.585039 |
| NTCR fellows | 0.742981 |
| engineer novel drug/antibody/siRNA | 0.668859 |
| human cancers | 0.551276 |
| core courses | 0.541397 |
| Training Focus | 0.565904 |
|
CLICK HERE |